SPONSORED ARTICLE
By Elric Langton | 1 February 2022
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces its wholly-owned subsidiary, ProBiotix Health Ltd, has carried out a consumer study (n=46) on its CholBiome® products.
CholBiome®X3 and CholBiome®BP ar…